Hubner K F, McDonald T W, Niethammer J G, Smith G T, Gould H R, Buonocore E
Biomedical Imaging Center, University of Tennessee Medical Center at Knoxville 37920.
Gynecol Oncol. 1993 Nov;51(2):197-204. doi: 10.1006/gyno.1993.1272.
The potential of positron emission tomography (PET) to distinguish benign from malignant ovarian tissue was evaluated by comparing the results of F-18 fluoro-2-D-deoxyglucose (F-18-FDG) PET scans with computed tomography and surgical findings. If sufficiently sensitive, this method might play a role in localizing metabolically active tumor sites for diagnosis, staging, and follow-up of ovarian cancer. Fifty-one patients had imaging studies prior to laparotomy for suspected ovarian cancer. PET scans were done with an ECAT 931-08-12 or ECAT EXACT (Model 921, Siemens/CTI, Knoxville, TN) after iv injection of 185-370 MBq of F-18-FDG. (ECAT is a trade name for "emission computerized axial tomograph.") Data were acquired in dynamic scanning mode and time activity curves (TACs) were evaluated in multiple regions of interest identified by visual interpretation of the PET scans. Scan interpretation, standardized uptake values, and TAC profiles were related to surgical and histological findings. The results of this pilot study show good correlation between PET and histological findings. The positive predictive value of PET for ovarian cancer was 86% and, perhaps more important, the negative predictive value was 76%. This early work indicates that PET may be useful in the management of patients with ovarian neoplasms by identifying occult foci of metabolically active tumor that do not appear on morphological studies.
通过比较F-18氟代-2-脱氧葡萄糖（F-18-FDG）正电子发射断层扫描（PET）与计算机断层扫描及手术结果，评估PET区分卵巢良性与恶性组织的潜力。如果该方法足够灵敏，可能在定位代谢活跃的肿瘤部位以用于卵巢癌的诊断、分期及随访中发挥作用。51例疑似卵巢癌患者在剖腹手术前行影像学检查。静脉注射185 - 370 MBq的F-18-FDG后，使用ECAT 931-08-12或ECAT EXACT（921型，西门子/CTI，田纳西州诺克斯维尔）进行PET扫描。（ECAT是“发射型计算机断层扫描仪”的商品名。）以动态扫描模式采集数据，并在通过PET扫描视觉解读确定的多个感兴趣区域评估时间 - 活性曲线（TACs）。扫描解读、标准化摄取值及TAC曲线与手术及组织学结果相关。这项初步研究结果显示PET与组织学结果之间具有良好的相关性。PET对卵巢癌的阳性预测值为86%，或许更重要的是，阴性预测值为76%。这项早期研究表明，PET可能有助于卵巢肿瘤患者的管理，通过识别形态学检查未显示的代谢活跃肿瘤隐匿灶。
